<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386800</url>
  </required_header>
  <id_info>
    <org_study_id>CINC424A2X01B</org_study_id>
    <secondary_id>2014-003527-22</secondary_id>
    <nct_id>NCT02386800</nct_id>
  </id_info>
  <brief_title>CINC424A2X01B Rollover Protocol</brief_title>
  <official_title>Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This roll-over protocol allows patients who are still receiving clinical benefit to continue&#xD;
      to be treated from multiple protocols in one program spanning multiple indications during the&#xD;
      completion of the parent study/(ies). The population for the roll-over study should be&#xD;
      consistent with the population defined in the program parent study/(ies). The primary&#xD;
      eligibility criteria for a patient to enter the roll-over protocol is the participation and&#xD;
      completion of a Novartis GDD&amp;GMA/Incyte study with ruxolitinib monotherapy or combination of&#xD;
      ruxolitinib and panobinostat. Efficacy parameters would not be measured; however safety data&#xD;
      and an evaluation of clinical benefit will be collected.&#xD;
&#xD;
      Patients who have completed a prior study with ruxolitinib monotherapy or combination of&#xD;
      ruxolitinib and panobinostat and who are assessed by the Investigator to continue to benefit&#xD;
      from ongoing treatment will be eligible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol number: CINC424A2X01B Full title An open label, multi-center, Phase IV rollover&#xD;
      protocol for patients who have completed a prior global Novartis or Incyte sponsored&#xD;
      ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study, and&#xD;
      are judged by the investigator to benefit from continued treatment.&#xD;
&#xD;
      Brief title An open label, multi-center, Phase IV rollover protocol to evaluate long term&#xD;
      safety data Sponsor and Clinical Phase: Novartis, IV Investigation type Drug Study type&#xD;
      Interventional Purpose and rationale The purpose of this study is to evaluate long term&#xD;
      safety data and to allow patients continued use of ruxolitinib monotherapy or combination of&#xD;
      ruxolitinib and panobinostat who have been receiving treatment in a Novartis-sponsored Global&#xD;
      Drug Development (GDD) or Global Medical Affairs (GMA) study or Incyte-sponsored study that&#xD;
      has reached its study objectives, are not progressing on the current study treatment as&#xD;
      defined by the parent protocol, have completed their obligations, and are unable to access&#xD;
      ruxolitinib or combination of ruxolitinib and panobinostat outside of a clinical trial.&#xD;
      Patients must be benefiting from treatment as judged by the investigator at the completion of&#xD;
      the parent study.&#xD;
&#xD;
      Primary Objective(s) To evaluate long term safety data i.e. SAEs and AEs Secondary Objectives&#xD;
      To evaluate clinical benefit as assessed by the investigator.&#xD;
&#xD;
      Study design This is a multi-center, open label study to evaluate long term safety of&#xD;
      ruxolitinib monotherapy or combination of ruxolitinib and panobinostat in patients from a&#xD;
      Novartis-sponsored Global Drug Development (GDD) or Global Medical Affairs (GMA) study or&#xD;
      Incyte-sponsored study that has reached its study objectives, or who are not progressing on&#xD;
      the current study treatment or who are on parent study and have completed their obligations&#xD;
      and are unable to access ruxolitinib or combination of ruxolitinib and panobinostat, outside&#xD;
      of a clinical study, and are benefiting from treatment as judged by the investigator at the&#xD;
      completion of the parent study.&#xD;
&#xD;
      Population Male and female patients who are currently enrolled in a Novartis-sponsored Global&#xD;
      Drug Development (GDD) or Global Medical Affairs (GMA) study or Incyte-sponsored study that&#xD;
      has reached its study objectives, or who are not progressing on the current study treatment&#xD;
      as defined by the parent protocol, or who are on parent study and have completed their&#xD;
      obligations and are unable to access ruxolitinib or combination of ruxolitinib and&#xD;
      panobinostat outside of a clinical study. Patients must be benefiting from treatment as&#xD;
      judged by the investigator at the completion of the parent study. This rollover study allows&#xD;
      patients from parent studies with indications including but not limited to myelofibrosis&#xD;
      (MF), polycythemia vera (PV), acute GvHD (aGvVHD) or chronic GvHD (cGvHD). The study must be&#xD;
      in the process of being completed &amp; reported.&#xD;
&#xD;
      For Pediatric GvHD Population*:&#xD;
&#xD;
      • Male and females ages ≥28 days to &lt;18 years old with either grade II-IV aGvHD or grade&#xD;
      II-IV SR-aGvHD or with either moderate to severe treatment-naive cGvHD or SR-cGvHD&#xD;
&#xD;
      *Pediatric GvHD population herein refers to both pediatric and adolescents from parent&#xD;
      protocols: CINC424F12201 (REACH-4) and CINC424G12201 (REACH-5).&#xD;
&#xD;
      Key Inclusion criteria Patient is currently enrolled in a Novartis-sponsored Global Drug&#xD;
      Development (GDD) or Global Medical Affairs (GMA) study or Incyte-sponsored study (where&#xD;
      Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to&#xD;
      enroll into this rollover study, and are receiving either ruxolitinib or combination of&#xD;
      ruxolitinib and panobinostat, and fulfilled all of the requirements of the parent protocol.&#xD;
&#xD;
      Patient is currently benefiting from the treatment with ruxolitinib monotherapy or&#xD;
      combination of ruxolitinib and panobinostat, as determined by the investigator.&#xD;
&#xD;
      Key Exclusion criteria Patient has been permanently discontinued from study treatment in the&#xD;
      parent study due to any reason.&#xD;
&#xD;
      Patient's indication is currently approved and reimbursed in the local country for&#xD;
      ruxolitinib monotherapy or other study drugs in the combination treatment (panobinostat).&#xD;
&#xD;
      Investigational and reference therapy INC424 / ruxolitinib / Jakavi / Jakafi (United States&#xD;
      [US] brand) LBH589 / panobinostat / Farydak Efficacy assessments At every quarterly visit,&#xD;
      the investigator is required to confirm that the patient continues to have clinical benefit&#xD;
      and may continue receiving ruxolitinib monotherapy or combination of ruxolitinib and&#xD;
      panobinostat.&#xD;
&#xD;
      Safety assessments Frequency and nature of adverse events and serious adverse events GvHD&#xD;
      Patient Population: At every quarterly visit, the investigator is required to confirm any&#xD;
      infections or, second primary malignancies under Adverse Events.&#xD;
&#xD;
      Pediatric GvHD population*: At every yearly visit, the investigator is to determine the&#xD;
      Tanner staging (if applicable).&#xD;
&#xD;
      *Pediatric GvHD population herein refers to both pediatric and adolescents from parent&#xD;
      protocols: CINC424F12201 (REACH-4) and CINC424G12201 (REACH-5).&#xD;
&#xD;
      Adolescent and Pediatric GvHD Patients: height and weight monitoring is required yearly by&#xD;
      the investigator until 18 years old.&#xD;
&#xD;
      Other assessments Not applicable Data analysis The statistical analysis will be descriptive&#xD;
      only, summarizing safety data and clinical benefit as assessed by the investigator, for the&#xD;
      overall population and by indication. The incidence of treatment emergent adverse events will&#xD;
      be summarized by system organ class and/or preferred term, type of adverse event, severity&#xD;
      (based on CTCAE grades), and relation to study treatment.&#xD;
&#xD;
      For pediatric GvHD patients ≤18 years of age, height and Body Mass Index (BMI) will be&#xD;
      summarized at yearly intervals, using descriptive statistics. All height/BMI data will be&#xD;
      listed. ingThe statistical analysis will mainly focus on be imited to report frequency and&#xD;
      severity of AEs and SAEs as outlined in Section 10.&#xD;
&#xD;
      Key words JAK inhibitor, Rollover Protocol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2010</start_date>
  <completion_date type="Anticipated">September 16, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>through study completion estimated to be approximately 12 years</time_frame>
    <description>Frequency and nature of adverse events and serious adverse events. GvHD Patient Population: At every quarterly visit, the investigator is required to confirm any infections or second primary malignancies under Adverse Events.&#xD;
Pediatric GvHD population*: At every yearly visit, the investigator is to determine the Tanner staging (if applicable).&#xD;
*Pediatric GvHD population herein refers to both pediatric and adolescents from parent protocols: CINC424F12201 (REACH-4) and CINC424G12201 (REACH-5).&#xD;
Adolescent and Pediatric GvHD Patients: height and weight monitoring is required yearly by the investigator until 18 years old</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical benefit as assessed by the investigator</measure>
    <time_frame>through study completion estimated to be approximately 12 years</time_frame>
    <description>Proportion of patients with clinical benefit as assessed by the investigator at scheduled visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Chronic Idiopathic Myelofibrosis</condition>
  <condition>Post Polycythemia Vera Myelofibrosis</condition>
  <condition>Post Essential Thrombocythaemia Myelofibrosis</condition>
  <condition>Steroid Refractory Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>ruxolitinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruxolitinib monotherapy. Patients are to use the study treatment based on the parent protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination of ruxolitinib + panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of ruxolitinib and panobinostat. Patients are to use the study treatment based on the parent protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib tablets or oral pediatric formulation, panobinostat capsules</intervention_name>
    <description>ruxolitinib tablets or oral pediatric formulation, panobinostat capsules</description>
    <arm_group_label>combination of ruxolitinib + panobinostat</arm_group_label>
    <other_name>INC424+LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib tablets or oral pediatric formulation</intervention_name>
    <description>ruxolitinib tablets or oral pediatric formulation</description>
    <arm_group_label>ruxolitinib monotherapy</arm_group_label>
    <other_name>INC424</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this study have to meet all of the following criteria:&#xD;
&#xD;
          1. Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored&#xD;
             clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if&#xD;
             applicable) that is approved to enroll into this rollover study, and are receiving&#xD;
             either ruxolitinib or combination of ruxolitinib and panobinostat, and fulfilled all&#xD;
             of the requirements of the parent protocol.&#xD;
&#xD;
          2. Patient is currently benefiting from the treatment with ruxolitinib monotherapy or&#xD;
             combination of ruxolitinib and panobinostat, as determined by the investigator&#xD;
&#xD;
          3. Patient has demonstrated compliance, as assessed by the investigator, with the parent&#xD;
             study protocol requirements&#xD;
&#xD;
          4. Willingness and ability to comply with scheduled visits, treatment plans and any other&#xD;
             study procedures&#xD;
&#xD;
          5. Patient currently has no evidence of progressive disease, as determined by the&#xD;
             investigator, following previous treatment with ruxolitinib or combination of&#xD;
             ruxolitinib and panobinostat&#xD;
&#xD;
          6. Written informed consent obtained prior to enrolling in rollover study and receiving&#xD;
             study medication. If consent cannot be expressed in writing, it must be formally&#xD;
             documented and witnessed, ideally via an independent trusted witness.&#xD;
&#xD;
        Note 1: If the patient is a minor, the parent who signs the informed consent for the minor&#xD;
        must be a legally recognized parent or guardian. Where deemed appropriate by the clinician,&#xD;
        and the child's parent or guardian, the child will also be included in the all discussions&#xD;
        about the trials and the minor aged 12 and above assent will be obtained. The parent or&#xD;
        guardian will sign on the designated line on the ICF attesting to the fact that the child&#xD;
        had given consent.&#xD;
&#xD;
        Note 2: if the minor is an adolescent female, she will be informed during the assent&#xD;
        process that for safety purpose, a pregnancy test is required. She will also be told that&#xD;
        if it is positive, she will be counseled and will be assisted in telling her parents. If&#xD;
        the minor does not want to proceed, she will be advised not to sign consent and her&#xD;
        enrollment in this protocol will end.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients eligible for this study must not meet any of the following criteria:&#xD;
&#xD;
          1. Patient has been permanently discontinued from study treatment in the parent study due&#xD;
             to any reason.&#xD;
&#xD;
          2. Patient's indication is currently approved and reimbursed in the local country.&#xD;
&#xD;
          3. Patient has participated in a combination trial other than the panobinostat and&#xD;
             ruxolitinib combination trial (CLBH589X2106), where ruxolitinib was dispensed in&#xD;
             combination with another study medication and until the termination of gestation,&#xD;
             confirmed by a positive hCG laboratory test.&#xD;
&#xD;
          4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test.&#xD;
&#xD;
          5. Female patients between ≥ 12 and &lt; 18 years of age and of childbearing potential (e.g.&#xD;
             are menstruating) who do not agree to abstinence or, if sexually active, do not agree&#xD;
             to the use of highly effective contraception as defined below, throughout the study&#xD;
             and for up to 30 days after stopping treatment.&#xD;
&#xD;
             Women of childbearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             throughout the study duration inclusive of the 30-day safety follow up. Highly&#xD;
             effective contraception methods include:&#xD;
&#xD;
               -  Total abstinence (when this is in line with the preferred and usual lifestyle of&#xD;
                  the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy), total hysterectomy or tubal ligation at least six weeks before&#xD;
                  taking study treatment. In case of oophorectomy alone, only when the reproductive&#xD;
                  status of the woman has been confirmed by follow up hormone level assessment&#xD;
&#xD;
               -  Male sterilization (at least 6 months prior to screening). For female patients on&#xD;
                  the study the vasectomized male partner should be the sole partner for that&#xD;
                  patient.&#xD;
&#xD;
               -  Use of oral, injected or implanted hormonal methods of contraception or placement&#xD;
                  of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of&#xD;
                  hormonal contraception that have comparable efficacy (failure rate &lt;1%), for&#xD;
                  example hormone vaginal ring or transdermal hormone contraception.&#xD;
&#xD;
             In case of use of oral contraception women should have been stable on the same pill&#xD;
             for a minimum of 3 months before taking study treatment.&#xD;
&#xD;
             Women are considered post-menopausal and not of childbearing potential if they have&#xD;
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile&#xD;
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago.&#xD;
             In the case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
             been confirmed by follow up hormone level assessment is she considered not of&#xD;
             childbearing potential.&#xD;
&#xD;
          6. For patients on the combination of ruxolitinib and panobinostat:&#xD;
&#xD;
               -  Women of childbearing potential unwilling to use highly effective methods of&#xD;
                  contraception during dosing and for 3 months (female patients of childbearing&#xD;
                  potential)&#xD;
&#xD;
               -  Female sexual partner(s) of childbearing potential of male participants unwilling&#xD;
                  to use highly effective methods of contraception during dosing and for 6 months&#xD;
                  after stopping.&#xD;
&#xD;
               -  Women of childbearing potential who use hormonal contraceptives and additionally&#xD;
                  unwilling to use a barrier method for birth control.Sexually active males&#xD;
                  (including vasectomised men) unwilling to use barrier contraception (condom with&#xD;
                  spermicide) during intercourse and for 6 months after stopping treatment (in&#xD;
                  order to prevent delivery of the drug via seminal fluid).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Franston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1413</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2540364</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goudi-Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6001</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H 6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita city</city>
        <state>Osaka</state>
        <zip>565 0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1099 023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7800</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0027</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0044</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lulea</city>
        <zip>SE 971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkoknoi</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <state>Sihhiye</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talas / Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelofibrosis polycythemia vera aGvVHD cGvHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

